Amgen (AMGN) Offering Possible 6.84% Return Over the Next 3 Calendar Days

Amgen’s most recent trend suggests a bearish bias. One trading opportunity on Amgen is a Bear Call Spread using a strike $190.00 short call and a strike $195.00 long call offers a potential 6.84% return on risk over the next 3 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $190.00 by expiration. The full premium credit of $0.32 would be kept by the premium seller. The risk of $4.68 would be incurred if the stock rose above the $195.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Amgen is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Amgen is bearish.

The RSI indicator is at 24.75 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Amgen

Ligand (LGND) Beats on Q4 Earnings & Sales, Raises ’19 View
Fri, 08 Feb 2019 13:03:01 +0000
Ligand (LGND) beats earnings and sales estimates for the fourth quarter of 2018 and raises 2019 guidance.

See what the IHS Markit Score report has to say about Amgen Inc.
Fri, 08 Feb 2019 13:00:37 +0000
Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company’s creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding AMGN totaled $16.03 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. AMGN credit default swap spreads are near their highest levels for the past 1 year, which indicates the market’s more negative perception of the company’s credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Amgen Falls 3%
Thu, 07 Feb 2019 10:52:02 +0000
Investing.com – Amgen (NASDAQ:AMGN) fell by 3.09% to trade at $184.86 by 10:51 (15:51 GMT) on Thursday on the NASDAQ exchange.

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down
Wed, 06 Feb 2019 14:37:02 +0000
Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

Roche Submits sBLA to FDA for Label Expansion of Kadcyla
Tue, 05 Feb 2019 14:02:02 +0000
Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Be Sociable, Share!

Related Posts